Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 503 of 5804
-
Hormone cocktail aims to stop rare salivary cancer recurrence
Disease control Recruiting nowThe purpose of the study is to evaluate the efficacy and safety of rezvilutamide in combination with androgen deprivation therapy (ADT) in participants with androgen receptor (AR) positive, high-risk salivary duct carcinoma (SDC). The procedures include screening, treatment and …
Phase: PHASE2 • Sponsor: Peking University First Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Smart AI could slash unnecessary prostate biopsies
Diagnosis CompletedProstate-specific antigen (PSA) testing has limited specificity for prostate cancer diagnosis, leading to a high rate of unnecessary biopsies. This multi-center study aims to develop and validate a non-invasive, multi-modal artificial intelligence model that combines cell-free DN…
Sponsor: Shanghai Changzheng Hospital • Aim: Diagnosis
Last updated Jul 25, 2026 00:00 UTC
-
Zap away heart flutters: new device trial offers hope for AF patients
Disease control Ongoing\### Study Overview * Study Name In simple terms, this study involves using a new device to treat a heart condition called "Paroxysmal Atrial Fibrillation." * Sponsor The study is sponsored by a company called Shanghai Shangyang Medical Technology Co., Ltd. * Trial Devices The …
Phase: NA • Sponsor: Shanghai Shangyang Medical Technology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug aims to tame lupus flares
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of IMC-002 and IMM0306S in the treatment of active SLE.
Phase: PHASE1, PHASE2 • Sponsor: ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Promising new therapy targets rare, aggressive cancers
Disease control Recruiting nowTo find out if ubamatamab, given by itself or in combination with cemiplimab, can help to control the disease in participants with renal medullary carcinoma (RMC) and epithelioid sarcoma (ES).
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New weekly Weight-Loss shot shows promise in Mid-Stage trial
Disease control CompletedThis study is designed to test how well MET097, an active drug, works to treat individuals with obesity or overweight when compared to placebo. MET097 or placebo will be given to individuals weekly for 28 weeks. If an individual is assigned to MET097 they will receive one of four…
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Could a weekly pill replace daily HIV meds? new study aims to find out.
Disease control OngoingThe goal of this clinical study is to learn about the safety and efficacy of switching to once weekly tablet of islatravir/lenacapavir (ISL/LEN) regimen versus continuing standard treatment of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people with human immunode…
Phase: PHASE3 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New drug could shrink rare joint tumors without surgery
Disease control OngoingThis is a multicenter, Phase 3, randomised, double-blind, placebo-controlled study, which aims to evaluate the efficacy and safety of the investigational drug emactuzumab for the treatment of patients with localized or diffuse TGCT where surgical removal of the tumor is not viewe…
Phase: PHASE3 • Sponsor: SynOx Therapeutics Limited • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New combo attack on aggressive breast cancer shows promise in early trial
Disease control Recruiting nowThis study is a prospective, single arm, multi-center phase II clinical trial. The primary study objective is to evaluate the pathologic complete response(PCR) of Adjuvant treatment of TNBC breast cancer with Toripalimab combined with neoadjuvant chemotherapy, including the incid…
Phase: PHASE2 • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New oral weight loss pill shows promise in Mid-Stage trial
Disease control CompletedA Phase IIb, global, randomized, parallel-group, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of AZD5004 compared with placebo, given once daily as an oral tablet(s) for 36 weeks, in male and female participants at least 18 years of age wh…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New targeted pill shows promise for rare bile duct cancer in Real-World study
Disease control Recruiting nowCholangiocarcinoma is a rare and aggressive tumor of the bile duct associated with a poor prognosis and very limited treatment options. The IDH1 inhibitor ivosidenib provides a new, targeted treatment option for this disease. Ivosidenib was approved by European Medicines Agency (…
Sponsor: iOMEDICO AG • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Could a pill replace the COVID-19 booster shot?
⭐️ VACCINE ⭐️ OngoingThe primary objective of the study is to determine the relative efficacy of the investigational oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine tablet VXA-CoV2-3.3 compared to a currently recommended vaccine for the prevention of symptomatic Coronavirus D…
Phase: PHASE2 • Sponsor: Vaxart • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 14:02 UTC
-
New shot could bring major relief for severe eczema sufferers
Disease control OngoingThis is a randomized, double-blind, placebo-controlled clinical trial with 500 participants. In this study, the safety evaluation used the common toxic reaction criteria of the National Cancer Institute to evaluate the adverse events of the drugs, and the effectiveness evaluation…
Phase: PHASE3 • Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New pill aims to keep narcolepsy patients awake and steady
Symptom relief CompletedThe main aim of this study is to learn how effective TAK-861 is in improving excessive sleepiness during the day (called excessive daytime sleepiness or EDS) after 3 months of treatment. Other aims are to learn how effective TAK-861 is in lowering the number of sudden, unexpected…
Phase: PHASE3 • Sponsor: Takeda • Aim: Symptom relief
Last updated Jul 18, 2026 00:00 UTC
-
New triple therapy aims to tackle tough leukemia mutation
Disease control Recruiting nowThe FMS tyrosine kinase 3 (FLT3) gene mutation occurs in 30% of newly diagnosed AML patients, leading to a higher relapse rate and mortality rate. In the past, multi-drug combination chemotherapy regimens had limited efficacy in newly diagnosed AML patients with FLT3 mutations, e…
Phase: PHASE1, PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New RSV vaccine shows promise for seniors in korea
⭐️ VACCINE ⭐️ CompletedThe goal of this clinical trial is to quantify the immune response in older Korean adults after a RSVpreF vaccination. It will also learn about the safety and tolerability of RSVpreF vaccination. The main questions it aims to answer are: What local reactions and systemic events …
Phase: PHASE3 • Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:03 UTC
-
Can telehealth stop HIV in its tracks? new study tests two approaches
Prevention Recruiting nowThe purpose of this study is to test 2 different ways to offer medications to prevent human immunodeficiency virus (HIV), cure hepatitis C virus (HCV) (if applicable) and treat substance use disorder (if desired) in people who inject drugs.
Phase: NA • Sponsor: University of Miami • Aim: Prevention
Last updated Jun 27, 2026 09:06 UTC
-
New personalized cancer vaccine shows promise in early trial
Disease control OngoingPhase I/II multicenter, open-label, single-arm trial in patients to evaluate the safety and effect of NECVAX-NEO1 administered in combination with PD-1/PD-L1 mABs in patients with solid tumors. Patients with solid tumors who will be treated with approved standard of care (SoC) PD…
Phase: PHASE1, PHASE2 • Sponsor: NEC Bio B.V • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Can a new drug slow Alzheimer's? major study launches
Disease control Recruiting nowThe main purpose of this study is to evaluate the long-term effectiveness of donanemab plus usual care versus usual care alone in participants with early symptomatic AD. The study will employ a prospective, observational cohort design with participant management resembling real-w…
Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New antitoxin aims to speed kidney recovery in kids with e. coli infection
Disease control Recruiting nowThe objectives of this study are to evaluate the efficacy, safety, and pharmacokinetics of INM004 in pediatric patients with Hemolytic Uremic Syndrome associated to infection by Shiga toxin-producing Escherichia coli (STEC-HUS).
Phase: PHASE3 • Sponsor: Inmunova S.A. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC